Opinion Opinion LONG Date Opinion Formed 04/28/08 Price Opinion Formed 3.90 Score -1 C-Rate 5.5 Recommendation Stock shows Mildly Deteriorating Conditions. SCORE = -1 If you are long, hold current position. Do not initiate new position. Stock is Not a Short Sell Candidate. Comment Moving Average Convergence/Divergence (MACD) indicates a Bullish Trend. Chart pattern indicates a Possible Trend Reversal Relative Strength is Bullish. Up/Down volume pattern indicates that the stock is under Distribution. The 50 day Moving Average is rising which is Bullish. The 200 day Moving Average is falling which is Bearish. Price is under Support of 3.76 which is Bearish. Watch for resistance at 3.77 Currently has No Position in ACTS. Just provide some material for those who are invested in ACTS.
5 reasons why the stock is in a slum: HCV-796 (Non-Nucleoside Polymerase Inhibitor to treat HepC) is dead due to renal toxicity in PII. The ever present threat of generic oral Vancomycin from Akorn. They raised 1/4 billion dollars (long term debt/convertibles) and the Street views it as negative. The two Phase 3s for Maribavir(Camvia) are on going. ViroPharma expects to file an NDA with the FDA and the EMEA at the same time in 2009. Not a sure thing under the eyes of the Street as they put a zero value for Camvia. A huge short percentage and naked shorts are preying on VPHM. Mixed all those 5 ingredients together and you have a stock which just tracks the market and goes nowhere for now.